Skip to content
Man mountains
News & Events

News & Events

Dr. Steven Gange Presents at AUA

UroLift® Proven Effective by Teleflex Studies

At the latest American Urological Association meeting, Dr. Steven Gange was selected to present on the effectiveness of UroLift® treatments. Dr. Gange presented on “Real World Outcomes of Prostatic Urethal Lift Confirm Clinical Study Results”, to highlight results of 1,413 UroLift® patients in North America and Australia. The results were consistent and show that UroLift® is an effective treatment option for many patients.

Click here to read the full article.

 

Teleflex: 100,000 Patients Treated for Enlarged Prostate with UroLift® System

Teleflex has announced that UroLift® minimally invasive BPH treatment has reached 100,000 patients treated worldwide. This is a new form of treatment that is gaining serious traction globally and is becoming the standard in the industry. Summit Urology Group’s own Dr. Steven Gange is a featured contributor in the AP article covering this milestone.

Read the full article here.

Dr. Steven Gange Featured in Urology Times

We are please to announce that Dr. Steven Gange is featured in the latest release of the Urology Times and it is now live and available for download on the Urology Times website. Dr. Gange was selected to sit on a panel of industry leaders to contribute to the publication about The Prostatic Urethral Lift Procedure using the UroLift® System due to his expertise in his field, his well-rounded experience, and for his extensive knowledge of UroLift and its advantages.

Download and read the full publication here!

Teleflex Incorporated Completes Acquisition of NeoTract

Wayne, PA — Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies designed to improve the health and quality of people’s lives, announced today the completion of its previously announced acquisition of NeoTract, Inc.

On September 5, 2017, the two companies announced a definitive agreement for Teleflex to acquire NeoTract in a transaction valued at up to $1.1 billion. Under the terms of the agreement, Teleflex acquired NeoTract for an upfront cash payment of $725 million at closing, and has agreed to pay up to an additional $375 million upon the achievement of certain commercial milestones related to sales through the end of 2020.

Founded in 2004, NeoTract is a privately-held medical device company that has developed and commercialized the FDA-cleared UroLift® System, a novel, minimally invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia, or BPH. Performed primarily through a transurethral outpatient procedure, the UroLift® System delivers permanent implants that hold open the urethra, reducing the prostate obstruction without cutting, heating, or removing prostate tissue.

Teleflex will provide additional details on the transaction, including an update to its fiscal year 2017 financial outlook as a result of this transaction, on its third quarter 2017 investor conference call.

ABOUT TELEFLEX INCORPORATED

Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose driven innovation – a relentless pursuit of identifying unmet clinical needs – to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular and interventional access, surgical, anesthesia, cardiac care, urology, emergency medicine and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit teleflex.com.
Teleflex is the home of Arrow®, Deknatel®, Hudson RCI®, LMA®, Pilling®, Rusch® and Weck® – trusted brands united by a common sense of purpose.

ABOUT NEOTRACT, INC.

NeoTract, Inc. is dedicated to developing innovative, minimally invasive and clinically effective devices that address unmet needs in the field of urology. The company’s initial focus is on improving the standard of care for patients with BPH using the UroLift System, a minimally invasive permanent implant system that treats symptoms while preserving normal sexual function. Learn more at www.NeoTract.com.

Help for Men With Enlarged Prostates

Enlarged prostates begin affecting about 50 percent of men in their 50s, and that number rises with age. As the prostate presses on the urethra, it can cause complications with urination, including slow or weak stream, the urgent need to urinate night and day, and accidental urination. Traditional treatments, typically medication or surgery, often come with undesirable side effects such as dizziness, headaches and significant issues with sexual dysfunction, which often makes men hesitant to pursue treatment.

As we celebrate men’s health month in June, we are taking a look at a minimally invasive procedure that is growing in popularity with urologists, some of whom are even using it for themselves. The prostatic urethral lift (PUL) procedure, known by the trade name UroLift, takes less than an hour and can be performed under local anesthesia in the doctor’s office.

Small UroLift implants are permanently placed to lift or hold the enlarged prostate tissue out of the way and increase the opening of the urethra to provide immediate symptom relief. The procedure does not involve cutting, heating or removal of prostate tissue.

 

The medical term for noncancerous enlarged prostate is benign prostatic hyperplasia (BPH), and it can interfere with sleep patterns and quality of daily life. A study published in the Journal of Urology stated that the condition affects 50 percent of men ages 51 to 60, and that the number increases to 80 percent by the time they reach their 70s. The UroLift System, which the FDA approved in 2013, involves inserting tiny implants that push the prostate off the urethra; UroLift’s producer, NeoTract Inc., likens it to tie-backs that hold window curtains open.  

Clinical data from a 206-patient randomized controlled study showed that men with enlarged prostates receiving UroLift implants reported rapid and durable improvement in their symptoms and urinary flow without compromising sexual function. Recovery is also faster than with traditional surgery, called transurethral resection (TURP), with minimal side effects, according to NeoTract. 

“This product has been a game changer for us,” says Gregg R. Eure, a urologist in Virginia Beach, Va., and assistant professor of urology at Eastern Virginia Medical School. “It is filling a niche that we haven’t had before. It takes less than one hour, and they are back to their regular routine quickly. It makes it very appealing to patients.” 

In the past, men would look at surgery as a last resort and wouldn’t do it until their enlarged prostate was so bad that they needed a catheter, Eure says. “But now they can address the symptoms earlier and enjoy the benefits longer.” In the NeoTract study, 14 percent of patients had to have additional treatment after the initial UroLift procedure, and there is some evidence that the traditional surgery may still offer better long-term urinary tract improvement. But the ease of the UroLift procedure and the minimal side effects still make it the better option for many patients, according to Eure, who participated in the procedure’s research trials.  

Over two years, Eure has done the procedure on nearly 200 patients with strong results, and he expects its popularity to rise now that it is reimbursed by Medicare and most other insurance plans. Other urologists agree. 

“I’ve followed the literature on the system from around the time it was FDA approved and became curious about it because it is a complete departure from the past,” says Peter J. Walter, a urologist in Jamestown, N.Y. “Surgery required cutting or heating and burning tissue, but this is a totally different way of managing the tissue. It is gently compressed and held in place by small tailored implants.”

Walter, an adviser to NeoTract, started using UroLift in his practice in 2015 and has performed the procedure on about 200 patients. Eventually, he started considering the procedure for himself. “I’m a 55-year-old man and was having symptoms [of BPH] myself and had to make a personal choice. I was not excited about medications because of the side effects, so I had [the UroLift] done in April of 2016 and it’s been great because my symptoms remarkably improved and I had no side effects.”

Walter is also relieved that he doesn’t have to take a pill every day, which he says is a bonus. “Some of my patients might be on 25 or 30 medications for different conditions, and who knows how those are all interacting,” he says.  

Not every patient is a perfect fit for the procedure due to anatomical differences with the prostate. If patients are interested they should speak with their primary care physician or urologist to get more information. A urologist may have more specific information about the procedure, Eure says. “As a urologist it is nice to feel confident that you are educating patients on a product that can really help them. You can see the change that it makes in their lives.”

Originally posted on aarp.org